JOHN HOPE FRANKLIN CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1838-01-01

Employees: 5K

Market Cap: -

Website: http://www.duke.edu

Clinical Trials

Transphyseal Vs. Physeal Sparing ACL Reconstruction in Skeletally Immature Patients: Risk of Subsequent Lower Extremity Growth Deformity

Completed

Conditions: ACL Reconstruction

Interventions: Diagnostic Test: Bilateral hip to ankle x-ray, exam and strength testing.

First Posted Date: 2017-03-15

Last Posted Date: 2020-10-08

Lead Sponsor: Duke University

Target Recruit Count: 49

Registration Number: NCT03081026

Locations: 🇺🇸
Duke Sports Science Institute, Durham, North Carolina, United States

PrEP for HBCUs (Study 2)

Not Applicable

Completed

Conditions: At Risk for HIV

Interventions: Device: PrEP Smart app

First Posted Date: 2017-03-15

Last Posted Date: 2019-01-31

Lead Sponsor: Duke University

Target Recruit Count: 16

Registration Number: NCT03080597

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes

Phase 4

Completed

Conditions: Lung Transplant Surgery
Heart Transplant Surgery

Interventions: Drug: iEPO
Drug: iNO

First Posted Date: 2017-03-15

Last Posted Date: 2023-02-16

Lead Sponsor: Duke University

Target Recruit Count: 519

Registration Number: NCT03081052

Locations: 🇺🇸
Duke Health, Durham, North Carolina, United States

DPE Technique in Labor Epidural for Morbidly Obese Women

Phase 4

Completed

Conditions: Morbid Obesity
Labor Pain

Interventions: Drug: Dural puncture epidural (DPE)
Drug: Standard Epidural (EPL)

First Posted Date: 2017-03-09

Last Posted Date: 2022-06-01

Lead Sponsor: Duke University

Target Recruit Count: 141

Registration Number: NCT03074695

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Early Recognition and Response to Increases in Surgical Site Infections Using Optimized Statistical Process Control Charts: The Early 2RIS Study

Not Applicable

Completed

Conditions: Infection Control
Surgical Site Infection

Interventions: Other: Intervention Cluster

First Posted Date: 2017-03-09

Last Posted Date: 2020-04-02

Lead Sponsor: Duke University

Target Recruit Count: 29

Registration Number: NCT03075813

Locations: 🇺🇸
Duke University Health System, Durham, North Carolina, United States

INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers

Early Phase 1

Completed

Conditions: Metastatic Urothelial Carcinoma
Metastatic Renal Cell Carcinoma
Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions: Drug: Isovue-M 200

First Posted Date: 2017-03-06

Last Posted Date: 2022-04-11

Lead Sponsor: Duke University

Target Recruit Count: 10

Registration Number: NCT03071328

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness

Phase 1

Completed

Conditions: Nicotine Addiction
Serious Mental Illness

Interventions: Device: Learn to Quit App
Drug: Nicotine patch
Drug: Nicotine lozenge
Behavioral: Technical Coaching
Device: NCI QuitGuide App

First Posted Date: 2017-03-03

Last Posted Date: 2020-11-10

Lead Sponsor: Duke University

Target Recruit Count: 63

Registration Number: NCT03069482

Locations: 🇺🇸
Duke University, Durham, North Carolina, United States

Stage Ib Trial of mSMART With Varenicline

Phase 1

Withdrawn

Conditions: Nicotine Dependence

Interventions: Device: mSMART
Drug: Chantix

First Posted Date: 2017-03-03

Last Posted Date: 2018-04-17

Lead Sponsor: Duke University

Registration Number: NCT03069768

Locations: 🇺🇸
Duke Health Behavior Neuroscience Research Lab, Durham, North Carolina, United States

Is There a Digital Divide in Chronic Kidney Disease (CKD)?

Not Applicable

Completed

Conditions: Chronic Kidney Disease

Interventions: Other: mHealth Tool

First Posted Date: 2017-03-01

Last Posted Date: 2018-10-09

Lead Sponsor: Duke University

Target Recruit Count: 580

Registration Number: NCT03067779

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
University of Maryland, Baltimore, Baltimore, Maryland, United States
🇺🇸
Duke University School of Medicine, Durham, North Carolina, United States

and more 1 locations

Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)

Phase 2

Completed

Conditions: Locally Advanced Esophageal and Gastric Cancers (EGC)

Interventions: Drug: Pembrolizumab

First Posted Date: 2017-02-27

Last Posted Date: 2024-03-13

Lead Sponsor: Duke University

Target Recruit Count: 35

Registration Number: NCT03064490

Locations: 🇺🇸
Duke Cancer Center, Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy